- Previous Close
0.0700 - Open
0.0700 - Bid 0.0690 x --
- Ask 0.0700 x --
- Day's Range
0.0690 - 0.0700 - 52 Week Range
0.0580 - 0.1850 - Volume
23,456 - Avg. Volume
525,914 - Market Cap (intraday)
46.358M - Beta (5Y Monthly) -0.60
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date Feb 26, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 4, 2023
- 1y Target Est
--
Vitura Health Limited engages in the sale and distribution of medicinal cannabis products in Australia. It operates through two segments: Sales and Distribution; and Clinics and Services. The company operates CanView, an online platform that delivers prescribing, dispensing, and medication management solutions for alternative therapies; Doctors on Demand, a premier provider of on-demand virtual healthcare services; BHC, an alternative therapy distributor; CDA Clinics, which provides medicinal consultations and prescription services; and Cannadoc, a medicinal cannabis clinic that offers telehealth consultations. It also offers psychedelics under the Cortexa brand; and Adaya which provides hybrid formulations and Australian-cultivated products. The company was formerly known as Cronos Australia Limited and changed its name to Vitura Health Limited in February 2023. Vitura Health Limited was incorporated in 2018 and is based in South Yarra, Australia.
vitura.com.au--
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: VIT.AX
View MorePerformance Overview: VIT.AX
Trailing total returns as of 4/17/2025, which may include dividends or other distributions. Benchmark is S&P/ASX 200 [XJO] (^AXJO) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VIT.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VIT.AX
View MoreValuation Measures
Market Cap
46.36M
Enterprise Value
56.90M
Trailing P/E
21.21
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.32
Price/Book (mrq)
1.13
Enterprise Value/Revenue
0.45
Enterprise Value/EBITDA
9.99
Financial Highlights
Profitability and Income Statement
Profit Margin
1.54%
Return on Assets (ttm)
2.67%
Return on Equity (ttm)
4.30%
Revenue (ttm)
126.57M
Net Income Avi to Common (ttm)
1.95M
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
7.4M
Total Debt/Equity (mrq)
44.30%
Levered Free Cash Flow (ttm)
-9.24M